journal
MENU ▼
Read by QxMD icon Read
search

Oncologist

journal
https://www.readbyqxmd.com/read/29330212/early-and-locally-advanced-metaplastic-breast-cancer-presentation-and-survival-by-receptor-status-in-surveillance-epidemiology-and-end-results-seer-2010-2014
#1
Mary C Schroeder, Priya Rastogi, Charles E Geyer, Lance D Miller, Alexandra Thomas
BACKGROUND: Metaplastic breast cancer (MBC) is a rare disease subtype characterized by an aggressive clinical course. MBC is commonly triple negative (TN), although hormone receptor (HR) positive and human epidermal growth receptor 2 (HER2) positive cases do occur. Previous studies have reported similar outcomes for MBC with regard to HR status. Less is known about outcomes for HER2 positive MBC. MATERIALS AND METHODS: Surveillance, Epidemiology, and End Results Program data were used to identify women diagnosed 2010-2014 with MBC or invasive ductal carcinoma (IDC)...
January 12, 2018: Oncologist
https://www.readbyqxmd.com/read/29330211/olanzapine-based-triple-regimens-versus-neurokinin-1-receptor-antagonist-based-triple-regimens-in-preventing-chemotherapy-induced-nausea-and-vomiting-associated-with-highly-emetogenic-chemotherapy-a-network-meta-analysis
#2
Zhonghan Zhang, Yaxiong Zhang, Gang Chen, Shaodong Hong, Yunpeng Yang, Wenfeng Fang, Fan Luo, Xi Chen, Yuxiang Ma, Yuanyuan Zhao, Jianhua Zhan, Cong Xue, Xue Hou, Ting Zhou, Shuxiang Ma, Fangfang Gao, Yan Huang, Likun Chen, Ningning Zhou, Hongyun Zhao, Li Zhang
BACKGROUND: The current antiemetic prophylaxis for patients treated with highly emetogenic chemotherapy (HEC) included the olanzapine-based triplet and neurokinin-1 receptor antagonists (NK-1RAs)-based triplet. However, which one shows better antiemetic effect remained unclear. MATERIALS AND METHODS: We systematically reviewed 43 trials, involving 16,609 patients with HEC, which compared the following antiemetics at therapeutic dose range for the treatment of chemotherapy-induced nausea and vomiting: olanzapine, aprepitant, casopitant, fosaprepitant, netupitant, and rolapitant...
January 12, 2018: Oncologist
https://www.readbyqxmd.com/read/29330210/trastuzumab-plus-pertuzumab-resistance-does-not-preclude-response-to-lapatinib-plus-trastuzumab-in-her2-amplified-colorectal-cancer
#3
Marwan G Fakih
Human epidermal growth factor 2 (HER2) amplification represents a distinct molecular subgroup of colorectal cancers that is associated with anti-epidermal growth factor receptor resistance and sensitivity to dual HER2 targeting. Although clinical trials have reported activity for trastuzumab/pertuzumab and trastuzumab/lapatinib combinations, there are no reports on lapatinib plus trastuzumab activity after resistance to trastuzumab plus pertuzumab. Presented are three cases of HER2 amplified colorectal cancer that developed acquired refractoriness to trastuzumab pertuzumab with subsequent clinical benefit to lapatinib plus trastuzumab, highlighting the potential for HER2 tyrosine kinase inhibition plus trastuzumab in overcoming trastuzumab/pertuzumab resistance...
January 12, 2018: Oncologist
https://www.readbyqxmd.com/read/29330209/cognitive-computing-to-guide-molecular-based-therapy-selection-steps-forward-amid-abundant-need
#4
Leif W Ellisen
No abstract text is available yet for this article.
January 12, 2018: Oncologist
https://www.readbyqxmd.com/read/29330208/neuroendocrine-tumor-heterogeneity-adds-uncertainty-to-the-world-health-organization-2010-classification-real-world-data-from-the-spanish-tumor-registry-r-getne
#5
Barbara Nuñez-Valdovinos, Alberto Carmona-Bayonas, Paula Jimenez-Fonseca, Jaume Capdevila, Ángel Castaño-Pascual, Marta Benavent, Jose Javier Pi Barrio, Alex Teule, Vicente Alonso, Ana Custodio, Monica Marazuela, Ángel Segura, Adolfo Beguiristain, Marta Llanos, Maria Purificacion Martinez Del Prado, Jose Angel Diaz-Perez, Daniel Castellano, Isabel Sevilla, Carlos Lopez, Teresa Alonso, Rocio Garcia-Carbonero
BACKGROUND: Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) are a complex family of tumors of widely variable clinical behavior. The World Health Organization (WHO) 2010 classification provided a valuable tool to stratify neuroendocrine neoplasms (NENs) in three prognostic subgroups based on the proliferation index. However, substantial heterogeneity remains within these subgroups, and simplicity sometimes entails an ambiguous and imprecise prognostic stratification. The purpose of our study was to evaluate the prognostic impact of histological differentiation within the WHO 2010 grade (G) 1/G2/G3 categories, and explore additional Ki-67 cutoff values in GEP-NENs...
January 12, 2018: Oncologist
https://www.readbyqxmd.com/read/29317554/bendamustine-plus-rituximab-versus-r-chop-as-first-line-treatment-for-patients-with-follicular-lymphoma-grade-3a-evidence-from-a-multicenter-retrospective-study
#6
Patrizia Mondello, Normann Steiner, Wolfgang Willenbacher, Claudio Cerchione, Davide Nappi, Endri Mauro, Simone Ferrero, Salvatore Cuzzocrea, Michael Mian
BACKGROUND: Rituximab plus bendamustine (R-B) has been demonstrated to improve outcomes and reduce toxicity compared with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHOP) in follicular lymphoma (FL). Nevertheless, in clinical practice, many centers still prefer R-CHOP to R-B in patients with FL grade 3A (FL3A). Therefore, we retrospectively assessed patients with FL3A treated with either R-CHOP or R-B in five European cancer centers and compared their outcomes. MATERIALS AND METHODS: We retrospectively assessed 132 patients affected by FL grade 3A treated with either R-B or R-CHOP in the first line and evaluated outcome and toxicity according to the type of treatment...
January 9, 2018: Oncologist
https://www.readbyqxmd.com/read/29317553/safety-profile-of-biosimilar-filgrastim-zarzio-zarxio-a-combined-analysis-of-phase-iii-studies
#7
Nadia Harbeck, Pere Gascón, Andriy Krendyukov, Nadja Hoebel, Sreekanth Gattu, Kimberly Blackwell
BACKGROUND: Evaluation of adverse events (AEs) in pivotal registration trials and ongoing postmarketing surveillance is important for all biologics, including biosimilars. A combined analysis of two pivotal registration studies was performed to strengthen evidence on safety for biosimilar filgrastim EP2006 in patients with breast cancer receiving myelosuppressive chemotherapy, a sensitive clinical setting to confirm biosimilarity of filgrastim. MATERIALS AND METHODS: Data were combined from two phase III studies of biosimilar filgrastim EP2006...
January 9, 2018: Oncologist
https://www.readbyqxmd.com/read/29317552/validation-and-refinement-of-the-age-comorbidities-and-albumin-index-in-elderly-patients-with-diffuse-large-b-cell-lymphoma-an-effective-tool-for-comprehensive-geriatric-assessment
#8
Hui Liu, Chun-Li Zhang, Ru Feng, Jiang-Tao Li, Yuan Tian, Ting Wang
BACKGROUND: We aimed to validate and refine the Age, Comorbidities, and Albumin (ACA) index in elderly Chinese patients with diffuse large B-cell lymphoma (DLBCL) and propose a more effective method for comprehensive geriatric assessment (CGA). MATERIALS AND METHODS: Patients ≥65 years of age who had been diagnosed with de novo DLBCL in the Institute of Hematology, Beijing Hospital, were screened for eligibility (n = 99). RESULTS: Based on the ACA index, 39, 31, 26, and 3 patients were categorized into the "excellent," "good," "moderate," and "poor" groups, respectively...
January 9, 2018: Oncologist
https://www.readbyqxmd.com/read/29317551/characteristics-of-real-world-metastatic-non-small-cell-lung-cancer-patients-treated-with-nivolumab-and-pembrolizumab-during-the-year-following-approval
#9
Sean Khozin, Amy P Abernethy, Nathan C Nussbaum, Jizu Zhi, Melissa D Curtis, Melisa Tucker, Shannon E Lee, David E Light, Anala Gossai, Rachael A Sorg, Aracelis Z Torres, Payal Patel, Gideon Michael Blumenthal, Richard Pazdur
BACKGROUND: Evidence from cancer clinical trials can be difficult to generalize to real-world patient populations, but can be complemented by real-world evidence to optimize personalization of care. Further, real-world usage patterns of programmed cell death protein 1 (PD-1) inhibitors following approval can inform future studies of subpopulations underrepresented in clinical trials. MATERIALS AND METHODS: We performed a multicenter analysis using electronic health record data collected during routine care of patients treated in community cancer care clinics in the Flatiron Health network...
January 9, 2018: Oncologist
https://www.readbyqxmd.com/read/29317550/fertility-sparing-treatment-of-endometrial-cancer-with-initial-infiltration-of-myometrium-by-resectoscopic-surgery-a-pilot-study
#10
Paolo Casadio, Francesca Guasina, Roberto Paradisi, Concetta Leggieri, Giacomo Caprara, Renato Seracchioli
Three women with a well-differentiated grade 1 endometrioid adenocarcinoma of the endometrium with minimal myometrial infiltration were treated with hysteroscopic resection and hormone therapy. The presence of myometrial infiltration has often been mentioned as an exclusion criterion for conservative management in young patients because of worsening cancer prognosis. The subsequent 5-year follow-up and the pregnancies achieved may confirm the choice of this temporary treatment and indicate a new option for fertility-sparing treatment in highly motivated patients...
January 9, 2018: Oncologist
https://www.readbyqxmd.com/read/29284761/refugees-in-conflict-creating-a-bridge-between-traditional-and-conventional-health-belief-models
#11
Eran Ben-Arye, Massimo Bonucci, Michel Daher, Rejin Kebudi, Bashar Saad, Thomas Breitkreuz, Maryam Rassouli, Elio Rossi, Nahla Gafer, Omar Nimri, Mohamed Hablas, Gunver Sophia Kienle, Noah Samuels, Michael Silbermann
The recent wave of migration from Middle Eastern countries to Europe presents significant challenges to the European health profession. These include the inevitable communication gap created by differences in health care beliefs between European oncologists, health care practitioners, and refugee patients. This article presents the conclusions of a workshop attended by a group of clinicians and researchers affiliated with the Middle East Cancer Consortium, as well as four European-based health-related organizations...
December 28, 2017: Oncologist
https://www.readbyqxmd.com/read/29284760/the-concept-of-biosimilars-from-characterization-to-evolution-a-narrative-review
#12
REVIEW
Fadi Farhat, Alfredo Torres, Wungki Park, Gilberto de Lima Lopes, Raja Mudad, Chukwuemeka Ikpeazu, Simon Abi Aad
Biologic agents are currently the fastest emerging segment of drug expenditure. Unlike chemically synthesized small-molecule drugs, biologics are more complex, medicinal products produced by a living organism. They have become part of the standard of care in the treatment of a large variety of diseases, such as growth disorders, autoimmune diseases, cancer, cardiovascular illnesses, hemophilia, and rare genetic conditions, to name a few. Biosimilars, which are copies of biologics that are highly similar, were introduced in the market with an aim to offer efficacy that is not clinically different from the originator or reference product, at lower prices...
December 28, 2017: Oncologist
https://www.readbyqxmd.com/read/29284759/portomesenteric-venous-stenting-for-palliation-of-ascites-and-variceal-bleeding-caused-by-prehepatic-portal-hypertension
#13
Rahul A Sheth, Sharjeel H Sabir, Philip Parmet, Roshon Amin, Joshua D Kuban, Steven Y Huang, Armeen Mahvash, David Fogelman, Milind Javle, Michael J Wallace
BACKGROUND: The purpose of this study was to evaluate percutaneous transhepatic portal vein stenting (PVS) for palliation of refractory ascites and/or variceal bleeding caused by extrahepatic portomesenteric venous stenosis in patients with pancreaticobiliary cancer. MATERIALS AND METHODS: A single-institution, retrospective review of patients who underwent PVS between January 2007 and July 2015 was performed. A total of 38 patients were identified, of whom 28 met the inclusion criterion of PVS performed primarily for refractory ascites or variceal bleeding...
December 28, 2017: Oncologist
https://www.readbyqxmd.com/read/29284758/barriers-and-explanatory-mechanisms-of-delays-in-the-patient-and-diagnosis-intervals-of-care-for-breast-cancer-in-mexico
#14
Karla Unger-Saldaña, Daniel Ventosa-Santaulària, Alfonso Miranda, Guillermo Verduzco-Bustos
BACKGROUND: Most breast cancer patients in low- and middle-income settings are diagnosed at advanced stages due to lengthy intervals of care. This study aimed to understand the mechanisms through which delays occur in the patient interval and diagnosis interval of care. MATERIALS AND METHODS: We conducted a cross-sectional survey including 886 patients referred to four major public cancer hospitals in Mexico City. Based in a conceptual model of help-seeking behavior, a path analysis strategy was used to identify the relationships between explanatory factors of patient delay and diagnosis delay...
December 28, 2017: Oncologist
https://www.readbyqxmd.com/read/29284757/autologous-stem-cell-transplantation-in-elderly-lymphoma-patients-in-their-70s-outcomes-and-analysis
#15
Lova Sun, Shuli Li, Areej El-Jawahri, Philippe Armand, Bimalangshu R Dey, David C Fisher, Eric D Jacobsen, Caron A Jacobson, Ann S LaCasce, Steven L McAfee, Thomas R Spitzer, Yi-Bin Chen, Zachariah DeFilipp
BACKGROUND: High-dose chemotherapy and autologous stem cell transplantation (ASCT) can offer durable remission in many patients with relapsed or high-risk lymphoma. However, elderly patients are often not considered ASCT candidates based on age alone. SUBJECTS, MATERIALS, AND METHODS: A retrospective analysis of patients ≥70 years of age with a diagnosis of Hodgkin or non-Hodgkin lymphoma receiving ASCT between 2000 and 2016 at two partner institutions was performed...
December 28, 2017: Oncologist
https://www.readbyqxmd.com/read/29259073/phase-ii-study-of-panitumumab-in-ras-wild-type-metastatic-adenocarcinoma-of-small-bowel-or-ampulla-of-vater
#16
Pat Gulhati, Kanwal Raghav, Rachna Shroff, Gauri Varadhachary, Milind Javle, Wei Qiao, Huamin Wang, Jeffrey Morris, Robert Wolff, Michael J Overman
LESSONS LEARNED: Panitumumab has no clinical activity in metastatic RAS wild-type small bowel adenocarcinoma (SBA) and ampullary adenocarcinoma (AAC), possibly due to the foregut and midgut derivation of small bowel and ampulla.These results, along with findings from genomic characterization of SBA, suggest that SBA represents a unique intestinal malignancy and treatments should not be habitually extrapolated from colorectal cancer.Further studies evaluating the benefit of targeted therapies exclusively in SBA and AAC are warranted...
December 19, 2017: Oncologist
https://www.readbyqxmd.com/read/29259072/racial-and-ethnic-composition-of-cancer-clinical-drug-trials-how-diverse-are-we
#17
Leslie J Dickmann, Jennifer L Schutzman
Many approved drugs demonstrate different pharmacokinetics, pharmacodynamics, and/or safety across racial and ethnic groups. The primary objective of the current study was to summarize the racial and ethnic makeup of cancer clinical drug trials using cancer drugs approved by the U.S. Food and Drug Administration (FDA) between January 1, 2010, and July 31, 2016. In clinical studies used for FDA approvals, 82.3% of participants identified as white, 10.2% as Asian, 2.3% as black, and 4.7% as Hispanic. Black participants made up 7...
December 19, 2017: Oncologist
https://www.readbyqxmd.com/read/29259071/extreme-prostate-specific-antigen-response-to-infusional-5-flourouracil-in-castrate-resistant-prostate-cancer
#18
Charlotte Manogue, Elisa Ledet, A Kumar Guddati, Brian Lewis, Oliver Sartor
Prostate cancer that has progressed after androgen deprivation, abiraterone, and taxane therapy is challenging to treat successfully. Herein we report a dramatic response to continuous-infusion 5-fluorouracil (5-FU) at a dose of 200 mg/m2 in a patient with rapidly progressive, heavily pretreated, metastatic castrate-resistant prostate cancer. Baseline prostate-specific antigen values declined from 1,890 ng/mL to <1 ng/mL after 5-FU therapy. We hypothesized that prostate-specific membrane antigen overexpression may result in cancer cells uniquely susceptible to antifolate therapies...
December 19, 2017: Oncologist
https://www.readbyqxmd.com/read/29242283/phase-ii-study-of-bez235-versus-everolimus-in-patients-with-mammalian-target-of-rapamycin-inhibitor-na%C3%A3-ve-advanced-pancreatic-neuroendocrine-tumors
#19
Ramon Salazar, Rocio Garcia-Carbonero, Steven K Libutti, Andrew E Hendifar, Ana Custodio, Rosine Guimbaud, Catherine Lombard-Bohas, Sergio Ricci, Heinz-Josef Klümpen, Jaume Capdevila, Nicholas Reed, Annemiek Walenkamp, Enrique Grande, Sufiya Safina, Tim Meyer, Oliver Kong, Herve Salomon, Ranjana Tavorath, James C Yao
LESSONS LEARNED: Treatment with BEZ235 has not been shown to demonstrate increased efficacy compared with everolimus and may be associated with a poorer tolerability profile.The hypothesis of dual targeting of the phosphatidylinositol 3-kinase and mammalian target of rapamycin pathways in patients with advanced pancreatic neuroendocrine tumors may warrant further study using other agents. BACKGROUND: This phase II study investigated whether targeting the phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) pathway via PI3K, mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2) inhibition using BEZ235 may be more effective than mTORC1 inhibition with everolimus in patients with advanced pancreatic neuroendocrine tumors (pNET) who are naïve to mTOR inhibitor therapy...
December 14, 2017: Oncologist
https://www.readbyqxmd.com/read/29242282/patient-reported-comorbidity-and-survival-in-older-adults-with-cancer
#20
Grant R Williams, Allison M Deal, Jennifer L Lund, YunKyung Chang, Hyman B Muss, Mackenzi Pergolotti, Emily J Guerard, Shlomit Strulov Shachar, Yue Wang, Kelly Kenzik, Hanna K Sanoff
BACKGROUND: Our ability to optimize the care of older adults with cancer and comorbid illnesses is insufficient because most clinical trials lack systematic measurement. The primary purpose of this study was to evaluate the association between patient-reported comorbidity and all-cause mortality using various comorbidity scoring algorithms. MATERIALS AND METHODS: The Carolina Senior Registry was linked with the North Carolina Central Cancer Registry to obtain mortality data...
December 14, 2017: Oncologist
journal
journal
20207
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"